Search - tctmd.com

Displaying 461 - 480 of 956

Sort: Relevancy | Date

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

October 14, 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 09, 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

Blood Pressure Insights in COVID-19: Watch for Drops and RAAS Red Flags

News Conference News

Blood Pressure Insights in COVID-19: Watch for Drops and RAAS Red Flags

September 10, 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

News Conference News ESC 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

Yael L. Maxwell

September 08, 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

September 04, 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

September 03, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

News Conference News ESC 2020

Got Mail? Letter-Based Intervention Doesn’t Boost OAC Initiation for A-fib

September 03, 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

News Conference News ESC 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Michael O'Riordan

September 01, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

August 31, 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

News Conference News ESC 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

August 31, 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

August 31, 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

August 30, 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

Trimetazidine Safe but Not Protective Long-term After PCI

News Conference News ESC 2020

Trimetazidine Safe but Not Protective Long-term After PCI

August 30, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.